Comparison
Omega-3 (DHA/EPA) vs Memantine (Namenda)
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | Omega-3 (DHA/EPA) | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 5–20mg |
| Half-life | 24h | 70h |
| Onset | — | 180min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 5200 | 4200 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Memantine (Namenda) are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) matches the evidence base of Memantine (Namenda) (evidence A, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist — blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.